

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of:

Michael D. BENTLEY et al.	Examiner:	Thomas Sweeney HEARD
Serial No.: 10/647,561	Art Unit:	1654
Filed: August 25, 2003	Confirmation No.:	3230
Title:	<b>POLYMER STABILIZED NEUROPEPTIDES</b>	

**Information Disclosure Statement Within Three Months of  
Application Filing or Before First Action – 37 C.F.R. §1.97(b)(4)**

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

**TIMING OF SUBMISSION**

This Information Disclosure Statement is being filed (1) within three months of the filing date of this application or date of entry into the national stage of an international application; or (2) before the mailing date of a first Office Action on the merits, after the filing of a Request for Continued Examination under 37 CFR §1.114, whichever occurs last in accordance with 37 CFR 1.97(b)(4).

Applicant(s) submit(s) the reference(s) in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make the citation(s) of official record in this application

**CITED INFORMATION**

In compliance with 37 CFR §1.98(a)(2), enclosed are copies of the following:  
(1) each foreign patent; (2) each publication or that portion which caused it to be listed, other than U.S. Patents and U.S. Patent Publications, unless required by the Office.

**EFFECT OF INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(h))**

This Information Disclosure Statement is not to be construed as a representation that: (1) a search has been made; (2) additional information material to the examination of this application does not exist; (3) these references are material; or (4) these references indeed constitute prior art.

If the Examiner applies any of the documents as prior art against any claim in the application and Applicant(s) determine that the cited documents do not constitute "prior art" under United States law, Applicant(s) reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicant(s) further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**FEE PAYMENT**

Applicant(s) believe(s) that no fees are due because this Information Disclosure Statement is being filed concurrently with a Request for Continued Examination (RCE).

However, if the Commissioner determines that any fee is due in order for this Information Disclosure Statement to be timely considered, the Commissioner is hereby authorized and requested to charge such fees and any additional fees to Deposit Account No. 50-0348.

Respectfully submitted on behalf of  
Nektar Therapeutics,

Date: February 16, 2011

By: /Mark A. Wilson/  
Mark A. Wilson, Reg. No. 43,275

**CORRESPONDENCE ADDRESS:**  
**CUSTOMER NO. 21968**

Nektar Therapeutics  
455 Mission Bay Boulevard South  
San Francisco, California 94158  
(415) 482-5300 (Telephone)  
(415) 339-5323 (Facsimile)